Načítá se...
An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease
BACKGROUND: The mTOR pathway, which consists of mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), is activated in polycystic kidney disease (PKD) kidneys. Sirolimus and everolimus indirectly bind and inhibit mTORC1. A novel group of drugs, the mTOR kinase inhibitors, directly bind to mTOR kinase,...
Uloženo v:
| Vydáno v: | Nephrol Dial Transplant |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4286761/ https://ncbi.nlm.nih.gov/pubmed/25239638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfu296 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|